The service reportedly costs up to $100,000 (£74,170) per month and offers access to posts from influential accounts milliseconds before they appear online.
Continue reading
BBC Business supplies a brief version of this story through its feed. Continue to the original publication for the complete report.
Read the original at BBC BusinessSources & methodology
Why is Trump Media selling early access to Trump's Truth Social posts?BBC Business
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm Sir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has been a triumph, starting with the against-the-odds victory over Pfizer’s charmless accountants in 2014. The $39bn (£29bn) purchase of Alexion in 2021 looked a little over-priced at the time, but you could see how it sat well with Soriot’s sermons on the importance of backing science. The deal got AZ into the field of medicines for rare diseases, which should offer decades of growth. Continue reading...
A former chief executive of Barclays has secured a £40m capital injection for the banking technology platform he launched a decade ago.
The former department store closed in 2016.